A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function

Melphalan 200 mg/m(2) is the standard conditioning regimen for patients with multiple myeloma (MM) with normal renal function (NRF) undergoing autologous stem cell transplant (ASCT). In an effort to escalate the dose of melphalan and to improve the efficacy, we designed a dose-escalation study of me...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Abidi, Muneer H., Agarwal, Rishi, Tageja, Nishant, Ayash, Lois, Deol, Abhinav, Al-Kadhimi, Zaid, Abrams, Judith, Cronin, Simon, Ventimiglia, Marie, Lum, Lawrence, Ratanatharathorn, Voravit, Zonder, Jeffrey, Uberti, Joseph
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3786738/
https://ncbi.nlm.nih.gov/pubmed/22892551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2012.08.003
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky